Skip to main navigation
Invivyd
  • About Us
    • Management Team
    • Board of Directors
  • Our Approach
    • Coronaviruses Background
    • Pipeline
    • Publications
  • Clinical Trials
  • Investors & Media
  • Partners
  • Careers
  • Contact
  • About Us
    • Management Team
    • Board of Directors
  • Our Approach
    • Coronaviruses Background
    • Pipeline
    • Publications
  • Clinical Trials
  • Investors & Media
  • Partners
  • Careers
  • Contact
  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
  • Analyst Coverage
  • Stock Information
    • Stock Quote & Chart
  • Financials & Filings
    • SEC Filings
  • Corporate Governance
    • Documents & Charters
    • Management
    • Board of Directors
    • Committee Composition
  • Resources
    • Investor FAQs
    • Email Alerts
    • Contact IR
  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
  • Analyst Coverage
  • Stock Information
    • Stock Quote & Chart
  • Financials & Filings
    • SEC Filings
  • Corporate Governance
    • Documents & Charters
    • Management
    • Board of Directors
    • Committee Composition
  • Resources
    • Investor FAQs
    • Email Alerts
    • Contact IR

Event Details

ECCMID 2022

Apr 23 - Apr 26, 2022

Supporting Materials

ADG20, a half-life–extended monoclonal antibody in development for the prevention and treatment of COVID-19, demonstrated broad in vitro neutralisation against SARS-CoV-2 variants 860.1 KB
Population pharmacokinetics of ADG20, an extended–half-life monoclonal antibody being developed for the treatment and prevention of COVID-19 1.2 MB
Invivyd

For general inquiries:
info@invivyd.com

For medical information
inquiries:
medinfo@invivyd.com

781-819-0080

  • Follow
  • Follow

1601 Trapelo Rd.
Suite 178
Waltham, MA 02451

Privacy Policy   |   Terms of Use   |   Cookie Policy